Abstract: Neoadjuvant chemotherapy has been widely used in the clinical treatment of breast cancer, the problem of how to apply accurate and simple method to predict the efficacy of neoadjuvant chemotherapy waited to be resolved. The review intends to explore the advantage of radiogenomics in predicting the efficacy of neoadjuvant chemotherapy for breast cancer by introducing a new research field - radiogenomics and expounding the current method of predicting breast cancer response to neoadjuvant chemotherapy.